Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18478128 | 0.84 | SMN1; SMN2 (0.46) | SMN1; SMN2 | |
| SCHEMBL17572101 | 0.80 | SMN1; SMN2 (0.42) | SMN1; SMN2 | |
| SCHEMBL24158929 | 0.80 | SMN1; SMN2 (0.42) | SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6208258 | 0.78 | SMN1; SMN2 (0.40) | SMN1; SMN2 | |
| SCHEMBL17572004 | 0.77 | SMN1; SMN2 (0.39) | SMN1; SMN2 | |
| SCHEMBL24904052 | 0.75 | CHRM2 (0.38) | SMN1; SMN2 | |
| SCHEMBL15431462 | 0.75 | SMN1; SMN2 (0.37) | SMN1; SMN2 | |
| SCHEMBL16727354 | 0.71 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL1922912 | 0.70 | — | — | |
| SCHEMBL18478138 | 0.69 | SMN1; SMN2 (0.36) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | SMN1; SMN2 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.